Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 6Thoracic 3Gastrointestinal 3Sarcoma 2NET 2Genitourinary 2Endocrine 2CNS 2Other solid neoplasm 1Head & Neck 1Dermatologic 1Breast 1

Conditions

Carcinoma, Neuroendocrine 5Neuroendocrine Tumors 2Neoplasms 2Lung Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Ovarian Epithelial 2Vipoma 1Stomach Neoplasms 1Somatostatinoma 1Small Cell Lung Carcinoma 1Sarcoma 1Pancreatic Neoplasms 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Mesothelioma 1Insulinoma 1Glucagonoma 1Glioblastoma 1Gastrointestinal Neoplasms 1Gastrinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

Vinorelbine 2Paclitaxel 2Irinotecan 2temsirolimus 1taxane 1liposomal doxorubicin 1entinostat 1Trastuzumab 1Sirolimus 1Ritonavir 1Radiotherapy 1RRx-001 1Pemetrexed 1PM 01183 1Nivolumab 1Microscopy, Electron 1Interleukin-12 Subunit p35 1Interleukin-12 1Indinavir 1Gemcitabine 1Fentanyl 1Etoposide 1Cisplatin 1Carboplatin 1CYT-6091 1Bortezomib 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × Irinotecan × Endocrine × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡